

# Researchers report innovative grass pollen allergy vaccine

June 2 2015

---

Biomay, a global leader in allergy immunotherapy, announced today that the results of a landmark phase IIb study with its 3rd generation grass pollen allergy vaccine BM32 will be reported at the EAACI Congress 2015 in Barcelona, Spain. This event is a major global scientific conference in the field of allergy and clinical immunology organized by the European Academy of Allergy and Clinical Immunology. The presentation titled "Clinical efficacy of a recombinant B cell epitope-based grass pollen allergy vaccine – a phase IIb proof of concept study" will be given by Prof. Rudolf Valenta, a globally recognized leader in allergy research, on June 7, 2015, in the Hot Topic Session of the congress.

The study, which was completed in 2014, provided convincing clinical proof of concept for this first-of-kind B-cell epitope derived [allergy](#) vaccine. It was observed that the Rhinoconjunctivitis Symptom Score (RSS) year was reduced by 25% compared to the placebo ( $p=0.042$ , statistically significant) in this 181-patient trial during the peak [pollen](#) season in the second treatment. The treatment also significantly improved patients' well-being measured by two independent methods (Visual Analogue Scale (VAS,  $p=0.014$ ) and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ),  $p$

Citation: Researchers report innovative grass pollen allergy vaccine (2015, June 2) retrieved 5 May 2024 from <https://medicalxpress.com/news/2015-06-grass-pollen-allergy-vaccine.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.